Details of the Drug Reposition

General Information of This Drug (ID: DMNAB57)

Drug Name
PRGN-3006   DMNAB57
Drug Type
CAR-T cell therapy

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelodysplastic syndrome DISYHNUI 2A37 Phase 1 [1]
Acute myeloid leukaemia DIS0BM1I 2A60 Phase 1 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03927261) A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients With CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome. U.S.National Institutes of Health.